Pharmaceutical Executive

Currax Pharmaceuticals CEO, George Hampton discusses what patient success has looked like for their oral anti-obesity medication, how expanded access can help with the world's obesity epidemic, when prices should come down, and much more.

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands. Featured in this episode are: Emma Banks, CEO, ramarketing Jill Jaroch, Senior Director, Women’s Health & Urology Marketing, Astellas Marie Teil, Global Head, UCB’s Women of Childbearing Age Program Julia Lakeland, Chief Product Office, uMotif If you enjoyed this episode of our podcast, we encourage you to seek out the longer version of each of these videos—Linked on our website!

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses their recent data and research about some massive behavioral shifts occurring across Gen-Z, and how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract the ever elusive generation.

Jingsong Wang, Chairman of Nona Biosciences, discusses Nona Biosciences’ recent exclusive license agreement with Pfizer Inc. for the development and commercialization of HBM9033, an innovative antibody-drug conjugate (ADC) targeting MSLN, a key antigen in various solid tumors. Wang believes that the partnership will significantly advance Nona's Harbour Mice® platform and ADC ecosystem.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

Sameer Lal, Sr. Vice President, Enterprise Medical Solutions at Indegene, discusses findings from their new study about Reshaping Pharmacovigilance in the age of AI, digital/generative AI opportunities, how quickly the industry is adopting this technology, and much more.

Dr. Julien Boisdron, Global Head of OneMedical / Chief Medical Officer Roche Diabetes Care, discusses the current standard for diabetes care, the importance of patient advocacy and mental health, what the future of this space holds, and much more.

Edward Triebell, Commercial Executive Director for MRN Technologies, discusses the biggest digital trends in clinical research right now, how COVID-19 impacted the use of digital within sponsors and CROs, what the future of DCT services looks like, and much more.

David Klein, co founder and CEO of Click Therapeutics, discusses the new FDA SaMD guidance, the clear differences between companion apps and SaMD, and gives insight into what to expect from this combination in the future.

In this exclusive Pharm Exec Podcast episode with Paul Biondi, executive partner at Flagship Pioneering (the venture creation firm behind Moderna and many other life science firms) and president of Pioneering Medicines, Meg Rivers, managing editor, asks Biondi about 1) the process of founding a company; 2) what factors they consider when deciding whether to partner with a pharmaceutical company (like your partnership with Novo Nordisk) or a foundation (like your partnership with the Cystic Fibrosis Foundation)—along with what makes one organization stand out from another; 3) where science is booming in pharma right now; 4) deciding whether to found a company looking to launch innovations in an existing space vs. pursue innovations in an untapped space; and 5) signs that a company will achieve commercial success from early on.

Commercialization is a tough road to navigate even for the most established bio/pharmaceutical therapies. But as cell and gene therapies (CGTs) continue to form roots and make a splash worldwide—but specifically in the US—commercialization forms its own version of standardization and best practices. In this exclusive interview with Pharmaceutical Executive, Lung-I Cheng, vice president of CGT, Cencora (formerly AmerisourceBergen), discusses: 1) defining CGT commercialization strategies and foundational knowledge—and the best music metaphor 2) what he wishes companies knew about commercialization strategies 3) common knowledge gaps of CGTs 4) how CGT developers can overcome key challenges, including those related to patient access, regulatory requirements, and market access 5) how planning for allogeneic cell therapies differs from autologous cell therapies and gene therapies 6) how companies can demonstrate CGT value as more products enter the development pipeline (and competition intensifies) 7) when to start planning a CGT commercialization strategy 8) predictions for the CGT market in five years

Gerald Kierce, co founder and CEO of Trustible and Andrew Gamino-Cheong, the company's CTO and co founder, delve into the realm of artificial intelligence discussing Trustible's mission and its pioneering efforts to ensure ethical AI use particularly in the pharmaceutical industry, and how it navigates complex AI regulations across the globe.

How to price a bio/pharmaceutical drug is one of the most complex topics for pharmaceutical executives, as there are many factors to consider. Alice Valder Curran, life sciences regulatory expert and partner, Hogan Lovells LLP, reveals the following to Pharmaceutical Executive® in this exclusive Pharm Exec Podcast interview: 1) the biggest drug pricing challenges today; 2) current efforts to lower drug pricing; 3) what companies should consider as it relates to drug pricing from a legal perspective; 3) the status of the Inflation Reduction Act (IRA), specifically what should companies be watching for; 4) potential impact on companies from the IRA; 5) IRA milestones we will be seeing through the end of the year; and 6) drug pricing recommendations (from a legal perspective). ACT podcast: https://www.appliedclinicaltrialsonline.com/editorial-podcasts

In this podcast, Sharlene Jenner, vice president of engagement strategy at Abelson Taylor and professor of AI and personalization for digital marketers at Southern Methodist University, leads a panel of five industry leaders in a roundtable discussion. The conversation delves into the practicalities of current AI applications and confronts the ethical and regulatory issues related to the technology. The panelists also explore the direct consequences and prospective implications of AI, providing listeners with a snapshot of the present and an outlook on the transformative potential of emerging technologies in the pharmaceutical marketing sphere. The panel consists of: Faruk Capan, chief innovation officer, EVERSANA, and CEO, EVERSANA INTOUCH; Anurag Banerjee, CEO and founder, Quilt.AI; Jeff Headd, vice president, commercial data science, The Janssen Pharmaceutical Companies of Johnson & Johnson; and Stephen Onikoro, senior principal, head of strategy, PharmaForceIQ. Sponsored by: ZS https://www.zs.com/

In this podcast, Mohit Manrao, the SVP and head of US oncology at AstraZeneca, shares his journey from growing up in Northern India with aspirations of becoming a doctor, to leading oncology initiatives at AstraZeneca in the US. A central strategy to ultimately eliminate cancer includes ensuring that the latest scientific advancements are accessible to patients in every zip code and the necessity of integrating the patient perspective at every stage—from early discovery to commercialization, recognizing the importance of diverse patient needs, non-invasive diagnostics, and alleviating challenges in access to screenings and treatments.

Welcome to a riveting episode of the Pharm Exec podcast, where we dive headfirst into the transformative world of AI in healthcare with Sharlene Jenner, vice president of engagement strategy with the award-winning agency Abelson Taylor. This enlightening conversation traverses the advancements and potential risks of AI, the revolution it is stirring in pharmaceutical marketing, and its game-changing role in understanding complex protein structures. Amid the rapid innovation, we explore the urgent need for ethical guidelines and regulations to keep pace with technology.

We all know that the pharma industry is about people—bettering the lives of others through good research, life-changing pharmaceuticals, and keeping the patient front and center. But Jag Dosanjh, president, US neuroscience and eye care, AbbVie, lives that principle. In this podcast episode, Meg Rivers, managing editor, talks with Dosanjh about what he calls a “people business” and his approach to leadership. He starts his career in the medical sales space before working in many different roles and therapeutic areas before ultimately landing at AbbVie. He was also nominated HBA’s mentor of the year and shares insights into being a good leader and mentor. One of his tips was: “If you listen well, you can learn well.” In addition, he emphasized the importance of curiosity, learning, and the pursuit of a smile.

This Pharma 50 companion episode delves into the vital topic of trust within the pharmaceutical industry. Morton Nielsen, senior partner for the life sciences practice at Wittkieffer, dissects the concept, drawing on parallels to Maslow's hierarchy of needs, and discusses practical methods for measuring and operationally improving trust. This episode is a must-listen for those interested in understanding the current state and future evolution of trust in the pharmaceutical sector, an industry where trust forms a fundamental pillar for delivering on its mission statement. Read the 2023 Pharma 50 article here: https://www.pharmexec.com/view/2023-pharm-exec-top-50-companies

The 2023 Emerging Pharma Leaders share with Meg Rivers, managing editor of Pharmaceutical Executive, and the editorial team what makes a good leader, what has made them the proudest in their career, lessons they wish they had known when starting out, and more. Congratulations to the 2023 Emerging Pharma Leaders: Natasha A. Hernday, chief business officer, Seagen; Simon Holland, vice president, women's health commercial lead, Organon; Justin To, chief operating officer, skeletal dysplasias and gene therapy, Bridge Bio; Frank Watanabe, president and CEO, Arcutis Biotherapeutics; and Hanadie Yousef, PhD, co-founder and CEO, Juvena Therapeutics. SPONSOR: APEX Awards https://www.pharmexec.com/apex-awards

Launching a drug and receiving approvals—whether it’s in the U.S. or globally—is challenging to navigate. It’s a process that often takes years and a lot of back-and-forth communication with regulatory bodies. In this episode, Torrey Cope, partner, food, drug, and medical device practice, Sidley Austin LLP, discusses drug approvals and drug launches from a legal perspective, including 1) his work as an attorney; 2) tips for drug approvals from a legal perspective; 3) current regulatory challenges the industry is facing in the U.S.; 4) the shift away from a one-sized-fits all approach to marketing and global launches; 5) tips for companies navigating the regulatory landscape in the U.S.; 6) when to launch a drug in a country outside of the U.S.; and 7) drug pricing. Join Meg Rivers, managing editor, as she dives into this topic with Cope.